Pharmacogenomics in Drug Discovery and Development Editor: Qing Yan

Status

Published

on 22 May 2008

Year of Creation

2007

Springer Science+Business Media LLC

Registration Number

TX0007230370

on 22 May 2008

The U.S. Copyright record (Registration Number: TX0007230370) dated 22 May 2008, pertains to an electronic file (eService) titled "Pharmacogenomics in Drug Discovery and Development Editor: Qing Yan" created in 2007. The copyright holder is Springer Science+Business Media LLC, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Springer Science+Business Media LLC.

Springer Science+Business Media LLC

Application Details

Registration Number

TX0007230370

Registration Date

5/22/2008

Year of Creation

2007

Agency Marc Code

DLC-CO

Record Status

New

Corporate Author

Springer Science+Business Media LLC

Physical Description

Book, 487 p

First Publication Nation

United States

ISBN

978-1-58829-887-4

Corporate Authors

Springer Science+Business Media LLC

Notes

Local Copyright Note: C.O. correspondence

Statements

Application Title Statement: Pharmacogenomics in Drug Discovery and Development Editor: Qing Yan

Author Statement: Springer Science+Business Media LLC employer for hire Authorship: Edited work with some new text

Notes

Local Copyright Note: C.O. correspondence

Statements

Application Title Statement: Pharmacogenomics in Drug Discovery and Development Editor: Qing Yan

Author Statement: Springer Science+Business Media LLC employer for hire Authorship: Edited work with some new text

Get your copyright registered todayThousands have copyrighted their assets.
What are you waiting for?

Show terms & conditions

Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.